Phase 1 Study of SAR440894 vs Placebo

Status Active, not recruiting

Clinical Trial Summary

A single, ascending-dose design with five dose-cohorts of 8 subjects. Forty healthy adults aged 18 to 45, inclusive, will be recruited and admitted at multiple sites. Each subject will be randomized to receive either SAR440894 or matching placebo via 60-minute intravenous infusion. In each cohort of 8 subjects, the randomization ratio will be 6 active to 2 placebo, and 2 sentinel subjects (one from each active and placebo group) will be dosed first. Dosing of the next dose-cohort will be dependent on acceptable meeting predefined safety criteria in the preceding cohort. Each subject's participation will take place over approximately 150 days, not including the screening visit. There are no hypotheses for this phase I study. The primary objective will be to determine the safety of single ascending intravenous (IV) infusions of SAR440894 when administered in healthy adults.

Clinical Trial Description

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04441905
Study type	Interventional
Source	National Institute of Allergy and Infectious Diseases (NIAID)
Contact
Status	Active, not recruiting
Phase	Phase 1
Start date	October 14, 2020
Completion date	September 28, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT02230163` - Clinical Evaluation of Anti-CHIKV Hyperimmune Intravenous Immunoglobulins	Phase 1/Phase 2
Completed	`NCT04546724` - Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in Adults	Phase 3
Terminated	`NCT04455919` - Yoga for Chronic Chikungunya	N/A
Completed	`NCT03631719` - Impact of Wolbachia Deployment on Arboviral Disease Incidence in Medellin and Bello, Colombia
Completed	`NCT02562482` - Trial for Safety and Immunogenicity of a Chikungunya Vaccine, VRC-CHKVLP059-00-VP, in Healthy Adults	Phase 2
Completed	`NCT03028441` - Phase I Trial of Measles Vectored Chikungungya Vaccine	Phase 1
Completed	`NCT03807843` - Chikungunya Vaccine (V184) Study in Previously Exposed Adults (V184-006)	Phase 2
Completed	`NCT04909411` - Consequences of a Maternal-fetal Chikungunya Virus Infection	N/A
Completed	`NCT04786444` - Study to Demonstrate Consistency of Three Lots of a Live-attenuated Chikungunya Virus Vaccine Candidate in Healthy Adults	Phase 3
Completed	`NCT02553369` - Seroprevalence of Chikungunya at the End of the First Chikungunya Outbreak in the French Antilles Within a Sample of Patients Treated for a HIV Infection	N/A
Recruiting	`NCT06106581` - A Phase 2 Clinical Study of VLA1553 in Healthy Children Aged 1 to 11 Years	Phase 2
Recruiting	`NCT06007183` - Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination	Phase 3
Completed	`NCT03635086` - Safety, Tolerability and Long-term Immunogenicity of Different Formulations of a Chikungunya Vaccine (V184-005)	Phase 2
Completed	`NCT02861586` - Phase II Study to Evaluate Safety and Immunogenicity of a Chikungunya Vaccine	Phase 2
Active, not recruiting	`NCT04838444` - Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine Candidate (VLA1553)	Phase 3
Completed	`NCT03483961` - Trial of a Chikungunya Vaccine, PXVX0317 CHIKV-VLP, in Healthy Adults	Phase 2
Recruiting	`NCT06028841` - A Clinical Phase 3 Study of VLA1553 in Adult Participants With Human Immunodeficiency Virus (HIV)	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.